Increasing evidence indicated that TMEM16A is also considered as a good target and potential biomarker for the treatment of gliomas (Liu et al., 2014), PDAC (Sauter et al., 2015) and LC (Jia et al., 2015). Here, ANO1 is linked to glioma.